OKYO Pharma Limited Publication of a Prospectus (6463X)

TIDMOKYO

RNS Number : 6463X

OKYO Pharma Limited

05 May 2021

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLYOR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the "Prospectus") in its final form that is published by OKYO Pharma Limited in connection with the admission of the Company's ordinary shares (the "Ordinary Shares") to listing on the standard segment of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange"). This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in the United States, Australia, Canada, Japan or in any other jurisdiction.

For immediate release

5 May 2021

OKYO Pharma Limited

("OKYO" or the "Company")

Prospectus Publication Announcement

OKYO Pharma Limited (LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain , announces the publication of its Prospectus in relation to the admission of a further 297,869,806 Ordinary Shares of no par value to listing on the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange (together, the "Admission").

Admission

It is expected that Admission will become effective and that dealings will commence at 8.00 a.m. on 7 May 2021.

The Prospectus will be available from the Company's registered office at Martello Court, Admiral Park, St Peter Port, Guernsey GY1 3HB and online at https://www.okyopharma.com/investors/corporate-documents (subject to applicable securities laws).

An electronic copy of the Prospectus will also be submitted to the National Storage Mechanism and should be available shortly for inspection at http:/data.fca.org/#nsm/nationalstoragemechanism.

.

OKYO Pharma Limited is a company incorporated in Guernsey with company number 65220. The Ordinary Shares are registered with ISIN GG00BD3FV870, SEDOL code BD3FV87 and TIDM OKYO.

End

Enquiries:

 
                            Gary S. Jacob, Chief Executive 
                             Officer 
                             Gabriele Cerrone, Non-Executive   [phone] 
OKYO Pharma Limited          Chairman                           2379 
 
Optiva Securities Limited                                      [phone] 
 (Broker)                   Robert Emmet                        4173 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PDIBGGDUGUGDGBU

(END) Dow Jones Newswires

May 05, 2021 06:53 ET (10:53 GMT)